Product Information
EDURANT 25 MG TABLET is a brand product labeled by Janssen Products LP, priced at $48.0410 per EA under NDC 59676027801. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 20, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Janssen Products LPNDC
59676027801
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RILPIVIRINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA202022FDA Approved
5/20/2011
TE Code
AB
On Market Since
5/20/2011
Pharmacological Classes
Price Statistics
The NADAC for EDURANT 25 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 109.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $48.0410 per EA |
|---|---|
| All-time high | $48.1197 (May 13, 2026) |
| All-time low | $22.8901 (Nov 28, 2013) |
| 52-week high | $48.1197 |
| 52-week low | $48.0356 |
| Median price | $37.5835 |
| Average price | $36.9476 |
| Largest weekly change | +7.9% (Jan 25, 2017) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the rilpivirine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Products LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rilpivirine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EDURANT 25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EDURANT 25 MG TABLET, manufactured by Janssen Products LP, is $48.0410 per EA (NDC 59676027801), effective Sep 30, 2026.
How has the price of EDURANT 25 MG TABLET changed over time?
Over the history we have for it, the NADAC for EDURANT 25 MG TABLET has risen 109.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EDURANT 25 MG TABLET?
Since Nov 28, 2013, the NADAC for EDURANT 25 MG TABLET has ranged from a low of $22.8901 (Nov 28, 2013) to a high of $48.1197 (May 13, 2026), with a median of $37.5835 per EA.
Are there cheaper alternatives to EDURANT 25 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of EDURANT 25 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EDURANT 25 MG TABLET?
EDURANT 25 MG TABLET (NDC 59676027801) is labeled by Janssen Products LP, and CMS classifies it as a brand product.